Tagrisso plus chemotherapy granted Priority Review in the US for patients with EGFR-mutated advanced lung cancer
Decision based on FLAURA2 Phase III trial results which extended median progression-free survival by nearly 9 months versus standard of care. AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would